Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 14/20 | 0.58 |
| ▸ | AKR1C2 | P52895 | 14/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.58 |
| ▸ | CDC42 | P60953 | 1/20 | 0.58 |
| ▸ | RAC1 | P63000 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.58 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31370526 | 1.00 | AKR1C3 (0.58) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL30564493 | 0.94 | AKR1C3 (0.54) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL21877367 | 0.86 | ROCK2 (0.46) | ROCK2ROCK1IMPDH2 | |
| Hydrochloric Acid SCHEMBL111598 | 0.84 | ROCK2 (0.45) | ROCK2ROCK1IMPDH2 | |
| SCHEMBL1492665 | 0.80 | APP (0.45) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL3128980 | 0.80 | UGT2B7 (0.58) | ROCK2ROCK1IMPDH2 | |
| SCHEMBL30087223 | 0.79 | PRKCZ (0.46) | ROCK2ROCK1IMPDH2 | |
| SCHEMBL1266869 | 0.79 | PRKCZ (0.46) | ROCK2ROCK1IMPDH2 | |
| SCHEMBL11470486 | 0.79 | AKR1C3 (0.69) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL10025981 | 0.78 | AKR1B1 (0.69) | AKR1C3AKR1C2PTGS2PTGS1CDC42 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118234-A1 | Urea Compounds as Gamma Secretase Modulators | AMGEN INC. | 2011-05-19 | — | — | US | disclosed |
| EP-2300427-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009137404-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118234-A1 | Urea Compounds as Gamma Secretase Modulators | BACE1, BACE2, PSEN1 | AKR1C3 3976/4885AKR1C2 3935/4885PTGS2 2052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.